Faculty Opinions recommendation of Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
2016 ◽
Vol 17
(4)
◽
pp. 425-439
◽
2017 ◽
Vol 18
(3)
◽
pp. 371-383
◽
2015 ◽
Vol 51
◽
pp. S270-S271
◽
2015 ◽
Vol 16
(13)
◽
pp. 1380-1388
◽